FH-A11KRASG12V-TCR
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for FH-A11KRASG12V-TCR, covering 2025-12-19 to 2025-12-19. Get the full timeline:
Most recent: Clinical Trial Update: Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations [Phase 1]